secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xeris Biopharma Holdings, Inc. (XERS)
CIK:        0001867096
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001867096-23-000121
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xeris exchanges $32M of 5% 2025 notes for $33.6M of 8% 2028 notes; extends debt maturity
--------------------------------------------------------------------------------

- Exchanged $31,975,000 of 5% convertible notes due 2025 for $33,574,000 of 8% notes due July 2028.
- Conversion price unchanged at ~$3.06 per share (~68% premium to Sept 26 closing price).
- Only ~$15.2M of original 2025 notes remain; no other debt due until 2027.
- Notes are senior unsecured; interest payable semi-annually starting Jan 15, 2024.
- Redeemable after July 20, 2026 if stock exceeds 130% of conversion price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000121/0001867096-23-000121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867096/000186709623000121/xers-20230926.htm
  HTML page:      https://secwatch.observer/filing/0001867096-23-000121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer